Search for 'an,phr: 431'

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.

By Grávalos Castro, Cristina. Targeted oncology, 2016 . 11(3):383-400. , Formato Vancouver: Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R et al. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol. 2016 Jun;11(3):383-400.

Place Hold on Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.

Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.

By Grávalos Castro, Cristina. Oncotarget, 2015 . 6(8):6422-30. , Formato Vancouver: García González X, Cortejoso L, García MI, García Alfonso P, Robles L, Grávalos C et al. Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer. Oncotarget. 2015 Mar 20;6(8):6422-30.

Place Hold on Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.

Seom guidelines for the treatment of gastric cancer 2015.

By Grávalos Castro, Cristina. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015 . 17(12):996-1004. , Formato Vancouver: Martin Richard M, Custodio A, García Girón C, Grávalos C, Gómez C, Jiménez Fonseca P et al. Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol. 2015 Dec;17(12):996-1004.

Place Hold on Seom guidelines for the treatment of gastric cancer 2015.

Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

By Grávalos Castro, Cristina. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2015 . ;26(3):535-41. , Formato Vancouver: Sotelo MJ, Sastre J, Maestro ML, Veganzones S, Viéitez JM, Alonso V et al. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. Ann Oncol. 2015 Mar;26(3):535-41.

Place Hold on Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.

By Grávalos Castro, Cristina. Molecular diagnosis & therapy, 2015 . 19(6):397-408. , Formato Vancouver: Llovet P, Sastre J, Ortega JS, Bando I, Ferrer M, García Alfonso P et al. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy. Mol Diagn Ther. 2015 Dec;19(6):397-408.

Place Hold on Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.

Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology.

By Grávalos Castro, Cristina. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015 . 17(10):763-71. , Formato Vancouver: Goday A, Barneto I, García Almeida JM, Blasco A, Lecube A, Grávalos C et al. Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2015 Oct;17(10):763-71.

Place Hold on Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology.

First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.

By Grávalos Castro, Cristina. European journal of cancer (Oxford, England: 1990), 2015 . 51(11):1371-80. , Formato Vancouver: Sastre J, Massuti B, Pulido G, Guillén Ponce C, Benavides M, Manzano JL; Spanish Cooperative Group for the Treatment of Digestive Tumours TTD. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J Cancer. 2015 Jul;51(11):1371-80.

Place Hold on First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.

Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.

By Manso Sánchez, Luis | Cortés-Funes Castro, Hernán | Grávalos Castro, Cristina. Anticancer research, 2015 . 35(12):6941-50. , Formato Vancouver: Manso L, Palomo AG, Pérez Carrión R, Cassinello J, Gallegos Sancho I, Chacón López-Muñiz I et al. Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study. Anticancer Res. 2015 Dec;35(12):6941-50.

Place Hold on Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.

By Grávalos Castro, Cristina. BMC cancer, 2015 . 15:327. , Formato Vancouver: García Alfonso P, Chaves M, Muñoz A, Salud A, García González M, Grávalos C et al; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. BMC Cancer. 2015 Apr 29;15:327.

Place Hold on Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.

A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.

By Grávalos Castro, Cristina. BMC cancer, 2015 . 15:60. , Formato Vancouver: Salazar R, Capdevila J, Laquente B, Manzano JL, Pericay C, Villacampa MM et al. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer. 2015 Feb 26;15:60.

Place Hold on A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.

TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.

By Grávalos Castro, Cristina. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of México. 2014 . 16(10):865-78. , Formato Vancouver: Benavides M, Abad A, Ales I, Carrato A, Díaz Rubio E, Gallego J et al. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Clin Transl Oncol. 2014 Oct;16(10):865-78.

Place Hold on TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.

A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O-6-Methylguanine-DNA Methyltransferase Promoter.

By Grávalos Castro, Cristina. Molecular cancer therapeutics, 2013 . 12(5):809-18. , Formato Vancouver: Hochhauser D, Glynne-Jones R, Potter V, Grávalos C, Doyle TJ, Pathiraja K et al. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther. 2013 May;12(5):809-18.

Place Hold on A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O-6-Methylguanine-DNA Methyltransferase Promoter.

SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013.

By Grávalos Castro, Cristina. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013 . 15(12):991-5. , Formato Vancouver: Maurel J, Grávalos C, Rivera F, Vera R, González Flores E; SEOM. SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013. Clin Transl Oncol. 2013 Dec;15(12):991-5.

Place Hold on SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013.

Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer.

By Grávalos Castro, Cristina. Clinical & Translational Oncology, 2013 . 15(9):705-11. , Formato Vancouver: Carrato A, Gómez A, Escudero P, Chaves M, Rivera F, Marcuello E et al. Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. Clin Transl Oncol. 2013 Sep;15(9):705-11.

Place Hold on Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer.

Tratamiento integral del cáncer de recto localizado

By Grávalos Castro, Cristina. Madrid: Fundación para la Investigación y Formación en Oncología, 2012 . p. 237-241 , Formato Vancouver: Grávalos C. Tratamiento integral del cáncer de recto localizado. En: Cortés-Funes H, coord. XXIV Curso Avanzado de la Oncología Médica, 20-23/junio/2012: San Lorenzo de El Escorial (Madrid). Madrid: Fundación para la Investigación y Formación en Oncología; 2012. p. 237-41.

Place Hold on Tratamiento integral del cáncer de recto localizado

SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma.

By Grávalos Castro, Cristina. Clinical and Translational Oncology, 2012 . 14(7):528-35. , Formato Vancouver: Rivera F, Grávalos C, García-Carbonero R. SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma. Clin Transl Oncol. 2012 Jul;14(7):528-35.

Place Hold on SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma.

First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study.

By Grávalos Castro, Cristina. Oncologist, 2012 . 17(3):339-45. , Formato Vancouver: Sastre J, Grávalos C, Rivera F, Massuti B, Valladares-Ayerbes M, Marcuello E, et al. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. Oncologist. 2012;17(3):339-45.

Place Hold on First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study.

Functions and workload of medical oncologists in Spain.

By Grávalos Castro, Cristina. Clinical & Translational Oncology, 2012 . 14(6):423-9. , Formato Vancouver: Grávalos C, Salvador J, Albanell J, Barnadas A, Borrega P, García-Mata J, et al. Functions and workload of medical oncologists in Spain. Clin Transl Oncol. 2012 Jun;14(6):423-9.

Place Hold on Functions and workload of medical oncologists in Spain.

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer.

By Cortés-Funes Castro, Hernán | Grávalos Castro, Cristina. Clinical & Translational Oncology, 2012 . 14(8):606-12. , Formato Vancouver: Gravalos C, Salut A, García-Girón C, García-Carbonero R, León AI, Sevilla I, et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clin Transl Oncol. 2012 Aug;14(8):606-12.

Place Hold on A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer.

Excelencia en oncología

By Cortés-Funes Castro, Hernán | Grávalos Castro, Cristina | Lanzos González, Eduardo | Martínez Hernández, Joaquín. Alcobendas, Madrid: Grupo Mensor, 2009 . 207 p. ; , Formato Vancouver: Alcaraz Quiñonero M, ÁLvarez Yeregi M, Ballestero Zárraga JJ, Barroeta Urquiza J, Bilbao Zulaica P, Blasco Pérez S, et al. Excelencia en oncología. Alcobendas, Madrid: Grupo Mensor; 2009. Guías Oncosur 24 cm..

Place Hold on Excelencia en oncología

First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)

By Grávalos Castro, Cristina. Critical Reviews in Oncology/Hematology, 2011 . 77(1):78-84. , Formato Vancouver: Sastre J, Aranda E, Grávalos C, Massutí B, Varella García M, Rivera F, et al. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol. 2011;77(1):78-84.

Place Hold on First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

By Cortés-Funes Castro, Hernán | Gómez Martín, Carlos | Grávalos Castro, Cristina. Clinical and Translational Oncology, 2011 . 13(3):179-184. , Formato Vancouver: Grávalos C, Gómez Martín C, Rivera F, Alés I, Queralt B, Márquez A, Jiménez U, Alonso V, et al. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol. 2011;13(3):179-84.

Place Hold on Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain

By Grávalos Castro, Cristina. Clinical & Translational Oncology, 2011 . 13(12):862-868. , Formato Vancouver: Grávalos C, García-Alfonso P, Afonso R, Arrazubi V, Arrivi A, Cámara JC, et al. Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain. Clin Transl Oncol. 2011;13(12):862-8.

Place Hold on Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain

Guía clínica de diagnóstico y tratamiento del carcinoma colorrectal

Place Hold on Guía clínica de diagnóstico y tratamiento del carcinoma colorrectal

Tratamiento adyuvante de las metástasis resecadas

By Grávalos Castro, Cristina | Ciruelos Gil, Eva María | Martínez Pueyo, José Ignacio | Gómez Martín, Carlos. . p. 181-196. , Formato Vancouver: Grávalos Castro C, Ciruelos Gil E, Martínez Pueyo JI, Gómez Martín C. Tratamiento adyuvantye de las metástasis resecadas. En: Díaz-Rubio E, coordinador. Cáncer colorrectal. Madrid: Ergon; 2000. p. 181-96.

Place Hold on Tratamiento adyuvante de las metástasis resecadas

Protocolo de carcinoma colorrectal 2004

By Alcalde Escribano, Juan Manuel | Arenas de Pablo, Ángel Emilio | De la Calle Santiuste, Ángel. | Colina Ruiz-Delgado, Francisco | Gómez Sanz, Ramón | Grávalos Castro, Cristina | Gutiérrez Santos, Eduardo | Ibarrola de Andrés, Carolina | Martínez Pueyo, José Ignacio | Morales Gutiérrez, Carlos | Muñoz Gómez, Raquel | Pascual Montero, José A. | Pérez Escutia, Mª Ángeles | Ruiz López, Pedro | Pulido Lanza, Ángeles. Madrid: Hospital Universitario 12 de Octubre, 2004 . 143 p. ; , Formato Vancouver: Subcomisión de Tumores Digestivos Hospital Universitario 12 de Octubre. Protocolo de carcinoma colorrectal 2004. Madrid: Hospital Universitario 12 de Octubre; 2004. 21 cm..

Place Hold on Protocolo de carcinoma colorrectal 2004

Guía clínica de diagnóstico y tratamiento del hepatocarcinoma

Place Hold on Guía clínica de diagnóstico y tratamiento del hepatocarcinoma

Guía clínica de diagnóstico y tratamiento del cáncer de esófago

Place Hold on Guía clínica de diagnóstico y tratamiento del cáncer de esófago

Protocolo Docente de Oncología Médica (2012)

By Grávalos Castro, Cristina | Manso Sánchez, Luis | Sepúlveda Sánchez, Juan Manuel. Madrid: Hospital Universitario 12 de Octubre, 2012 . 17 p. ; 30 cm..

Place Hold on Protocolo Docente de Oncología Médica (2012)